LCTX · Lineage Cell Therapeutics, Inc.
AI read · Neutral
The AI's read
That gives Lineage a new Huntington's disease treatment program already being tested in people. California's regenerative medicine agency has supported its development. The current study checks safety, not whether the treatment works. Lineage must also pay part of the study costs and take responsibility for later development and manufacturing. The deal includes share payments and more payments if the program reaches milestones. With no patient results reported, the program's promise and added costs point in different directions.